Volume 7.16 | May 8

Immune Regulation News 7.16 May 8, 2015
Immune Regulation News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Like Us on Facebook  IRN on Twitter
Combined Chemotherapy and Immunotherapy Shows Promise for Advanced Prostate Cancers
Researchers found that blocking or removing immune-suppressing cells allows a special type of chemotherapy—and the immune cells it activates—to destroy prostate tumors. [Press release from UC San Diego discussing online publication in Nature] Press Release | Abstract
Request a Sample: 8 minutes to highly purified immune cells with EasySep™.
PUBLICATIONS (Ranked by impact factor of the journal)
Peripheral Regulatory T Lymphocytes Recirculating to the Thymus Suppress the Development of Their Precursors
Investigators found that the output of new regulatory T cells (Treg cells) from the thymus decreased substantially more than that of conventional T cells. In the thymus, recirculating Treg cells exerted their regulatory function by inhibiting interleukin 2-dependent de novo differentiation of Treg cells. [Nat Immunol] Abstract

IFN-λ Resolves Inflammation via Suppression of Neutrophil Infiltration and IL-1β Production
Investigators showed that treatment with interferon (IFN)-λ2/IL-28A completely halted and reversed the development of collagen-induced arthritis and discovered cellular and molecular mechanisms of IL-28A anti-inflammatory function. [J Exp Med] Abstract

Id1 Suppresses Anti-Tumor Immune Responses and Promotes Tumor Progression by Impairing Myeloid Cell Maturation
Scientists demonstrated that upregulation of the inhibitor of differentiation 1 (Id1), in response to tumor-derived factors, such as TGFβ, was responsible for the switch from dendritic cell differentiation to myeloid-derived suppressor cell expansion during tumor progression. [Nat Commun] Full Article | Press Release

Manipulation of B-Cell Responses with Histone Deacetylase Inhibitors
Researchers examined the ability of histone deacetylase inhibitors (HDACi) to modify both protective and autoimmune antibody responses. In vitro, HDACi affected B-cell proliferation, survival and differentiation in an HDAC-class-dependent manner. [Nat Commun] Abstract

Porous Silicon Microparticle Potentiates Anti-Tumor Immunity by Enhancing Cross-Presentation and Inducing Type I Interferon Response
Scientists report a porous silicon microparticle (PSM)-based cancer vaccine that greatly enhanced cross-presentation and activates type I interferon response in dendritic cells. PSM-loaded antigen exhibited prolonged early endosome localization and enhanced cross-presentation through both proteasome- and lysosome-dependent pathways. [Cell Rep] Full Article | Graphical Abstract | Press Release

De Novo-Induced Self-Antigen-Specific Foxp3+ Regulatory T Cells Impair the Accumulation of Inflammatory Dendritic Cells in Draining Lymph Nodes
Scientists demonstrated that infusion of myelin in wild-type (WT) mice results in the de novo induction of myelin-specific Foxp3+ regulatory T cells in WT mice and amelioration of experimental autoimmune encephalomyelitis. [J Immunol] Abstract

Radiation-Driven Lipid Accumulation and Dendritic Cell Dysfunction in Cancer
The authors report findings on the dysfunction of dendritic cells (DCs) in radiation-induced thymic lymphomas, and the up-regulation of the expression of the lipoprotein lipase and the fatty acid binding protein, and the level of triacylglycerol in serum after total body irradiation, which contribute to DCs lipid accumulation. [Sci Rep] Full Article

A GMCSF and IL7 Fusion Cytokine Leads to Functional Thymic-Dependent T-Cell Regeneration in Age-Associated Immune Deficiency
Previous work has demonstrated that γc cytokines fused with granulocyte-macrophage colony stimulating factor (GMCSF) at the N-terminus acquire unheralded biological properties. To enhance thymopoiesis, scientists developed a novel biopharmaceutical based on the fusion of GMCSF and interleukin-7 (GIFT7). During murine cytomegalovirus infection of aged animals, GIFT7-mediated neo-thymopoiesis led to increased absolute numbers of viral-specific CD8+ T cells. [Clin Transl Immunol] Full Article

Don’t forget to subscribe to Human Immunology News and Immunology of Infectious Disease News!

Isolate Immune Cells From Whole Blood Without Lysis or Centrifugation with EasySep™ Direct. Request a Free Sample!
Intestinal Barrier Loss as a Critical Pathogenic Link between Inflammatory Bowel Disease and Graft-versus-Host Disease
The authors discuss similarities between inflammatory bowel disease and graft-versus-host disease, mechanisms of intestinal barrier loss in these diseases, and the crosstalk between barrier loss and the immune system, with a special focus on natural killer cells. [Mucosal Immunol] Abstract

The Macrophage Migration Inhibitory Factor Protein Superfamily in Obesity and Wound Repair
The macrophage migration inhibitory factor (MIF) superfamily consists of MIF and the recently identified homolog d-dopachrome tautomerase. Their respective roles in adipose tissue homeostasis, adipose tissue inflammation, insulin resistance and impaired wound healing are reviewed. [Exp Mol Med] Full Article

Visit our reviews page to see a complete list of reviews in the immune regulation research field.

Your Favorite Immunology Newsletters Are Now on Facebook! Like Us Today!
Biothera to Present Additional Data on Imprime PGG’s Potential to Alleviate Tumor-Mediated Immunosuppression
Additional data showing Biothera’s investigational cancer immunotherapy Imprime PGG can alleviate tumor-mediated immunosuppression and potentially strengthen the body’s ability to recognize and kill tumor cells will be presented. [Press release from Biothera, The Immune Health Company discussing research to be presented at the 2015 American Association of Immunologists (AAI) Annual Meeting, New Orleans]
Press Release | Poster

Kadmon Corporation Presents Data on Role of ROCK2 Inhibition
Kadmon Corporation, LLC, announced preclinical data defining the role of ROCK2 (Rho-associated coiled-coiled kinase 2) in regulating immune response at the cellular level. [Press release from Kadmon Corporation, LLC discussing research to be presented at the 2015 American Association of Immunologists (AAI) Annual Meeting, New Orleans] Press Release

Argos Therapeutics to Present at 36th American Society for Apheresis Annual Meeting
Argos Therapeutics Inc. will present findings on leukapheresis collection from the ongoing pivotal ADAPT Phase III clinical trial evaluating AGS-003, Argos’s fully personalized immunotherapy for the treatment of metastatic renal cell carcinoma. [Press release from Argos Therapeutics Inc. discussing research to be presented at the 36th American Society for Apheresis Annual Meeting, San Antonio] Press Release

From our sponsor:
Quickly find the whole-blood frequencies of human and mouse immune cell types.
Download the app.
LRI Joins Major New Collaboration to Understand Lupus Genetics
The Lupus Research Institute (LRI) will collaborate on important research to understand the genetics of lupus and to accelerate development of new treatments. Spearheaded by personal genetics company 23andMe in partnership with Pfizer Inc., the study will analyze the genetic make-up of thousands of people with lupus alongside their health history and environmental factors. [Lupus Research Institute] Press Release

Plexxikon and Merck to Collaborate on Combination Study Evaluating Investigational Immuno-Oncology Regimen
Plexxikon Inc. and Merck announced a collaborative clinical trial that will evaluate the combination of PLX3397, Plexxikon’s investigational CSF-1R inhibitor, and KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, which provides the potential for a double blockade of cancer-induced immune suppression. [Plexxikon Inc.] Press Release

NanoString Technologies and Cancer Immunotherapy Trials Network (CITN) Enter into a Collaboration to Identify Biomarker Assays for Novel Cancer Immunotherapies
CITN and NanoString Technologies, Inc. announced a multi-year translational research collaboration to discover biomarkers that predict clinical outcomes for cancer immunotherapies, both as single agents and in combination. [NanoString Technologies, Inc.] Press Release
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW 45th Annual Scientific Meeting of the Australasian Society for Immunology
November 29-December 3, 2015
Canberra, Australia

Visit our events page to see a complete list of events in the immune regulation community.
NEW Scientist – Immunology and Cell Separation (STEMCELL Technologies Inc.)

NEW Research Associate – Cell Separation (STEMCELL Technologies Inc.)

NEW Postdoctoral Researcher – Autoimmunity and Antibody Engineering (Karolinska Institutet)

Project Leader – Immunology (Cellectis Inc.)

Postdoctoral Fellow – Immunology (Boston Children’s Hospital)

Postdoctoral Fellow – Genomic and Immunogenomic Aspects of Lymphomas (University of Chicago)

Principal Scientist – Antibody Discovery, Biologics Research (Janssen Research & Development LLC.)

Postdoctoral Fellow – Immunopathogenesis of Multiple Sclerosis (University of Iowa)

Senior Scientist – Immunology (National Institute of Immunology)

Assistant Professor – Immunology (Northwestern University)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Immune Regulation News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Immune Regulation News: Archives | Events | Contact Us